Skip to main content

Differential Mapping of Intracellular Metallic Nanoparticles and Ions and Dynamic Modeling Prediction.

ACS nano2025-06-04PubMed
Total: 84.0Innovation: 9Impact: 0Rigor: 0Citation: 0

Summary

Using dual-modal live-cell imaging plus kinetic modeling, the study quantifies how much toxicity arises from intact metallic nanoparticles versus their dissolved ions. Across Ag, CuO, and ZnO systems (20–100 nm) and 0–100 mg/L exposures, ionic species accounted for the majority of toxicity with distinct material-specific profiles, providing a mechanistic basis to design safer nano-enabled formulations.

Key Findings

  • 2.68–34.7% of internalized MNPs dissolved intracellularly post-uptake; smaller particles released 1.08–1.22× more ions.
  • Ions dominated toxicity: 59.7–79.4% (AgNPs), 69.6–100% (CuO-NPs), 97.7% (ZnO-NPs) across 0–100 mg/L.
  • Distinct toxicity shapes by material: Ag biphasic, CuO logistic-like, ZnO entirely ion-driven.
  • An integrative model mechanistically linked extracellular dissolution, uptake, intracellular transformation, and toxicity pathways.

Clinical Implications

Risk assessment for nano-enabled cosmetics should prioritize controlling ionic release (e.g., coatings, particle size, matrix effects). Regulatory toxicology can incorporate ion-dominant mechanisms into exposure limits and formulation guidance.

Why It Matters

First integrated real-time mapping of nanoparticles and ions with a mechanistic toxicity model that generalizes across commonly used cosmetic-relevant materials (Ag, ZnO). Provides actionable parameters (dissolution and ion contribution) for safety-by-design.

Limitations

  • In vitro/cell-based systems; lack of in vivo validation.
  • Particle types limited to Ag, CuO, ZnO (20–100 nm) and concentration window 0–100 mg/L.

Future Directions

Validate predictions in organotypic/animal models; extend to coated/composite nanoparticles and consumer-relevant matrices to define dissolution-controlling formulation strategies.

Study Information

Study Type
Case series
Research Domain
Pathophysiology
Evidence Level
V - Nonclinical mechanistic study with live-cell imaging and modeling; no human/animal outcomes.
Study Design
OTHER